BR112016002738A2 - diacorpo de fc monovalente biespecífico, composição farmacêutica, e, uso da composição farmacêutica - Google Patents

diacorpo de fc monovalente biespecífico, composição farmacêutica, e, uso da composição farmacêutica

Info

Publication number
BR112016002738A2
BR112016002738A2 BR112016002738A BR112016002738A BR112016002738A2 BR 112016002738 A2 BR112016002738 A2 BR 112016002738A2 BR 112016002738 A BR112016002738 A BR 112016002738A BR 112016002738 A BR112016002738 A BR 112016002738A BR 112016002738 A2 BR112016002738 A2 BR 112016002738A2
Authority
BR
Brazil
Prior art keywords
bispecific monovalent
pharmaceutical composition
bodies
cd32b
cd79b
Prior art date
Application number
BR112016002738A
Other languages
English (en)
Other versions
BR112016002738B1 (pt
Inventor
Bonvini Ezio
Shah Kalpana
s johnson Leslie
Huang Ling
A Moore Paul
Chen Wei
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of BR112016002738A2 publication Critical patent/BR112016002738A2/pt
Publication of BR112016002738B1 publication Critical patent/BR112016002738B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

resumo diacorpo de fc monovalente biespecífico, composição farmacêutica, e, uso da composição farmacêutica a presente invenção é direcionada a diacorpos monovalentes biespecíficos que compreendem um domínio de fc de imunoglobulina ("diacorpos de fc monovalentes biespecíficos") e são compostos de três cadeias de polipeptídeo e que possuem pelo menos um sítio de ligação específico para um epitopo de cd32b e um sítio de ligação específico para um epitopo de cd79b (isto é, um "diacorpo de fc monovalente biespecífico de cd32b x cd79b"). os diacorpos de fc monovalentes biespecíficos da presente invenção são capazes de ligação simultânea a cd32b e a cd79b. a invenção é direcionada a tais composições, a composições farmacêuticas que contêm tais diacorpos de fc monovalentes biespecíficos e a métodos para seu uso no tratamento de doenças ou condições inflamatórias, e em particular, lúpus eritematoso sistêmico (sle) e doença enxerto versus hospedeiro. 1/1
BR112016002738-8A 2013-08-09 2014-08-06 Diacorpo de fc monovalente biespecífico, composição farmacêutica, uso do diacorpo de fc monovalente biespecífico, e uso da composição farmacêutica BR112016002738B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361864217P 2013-08-09 2013-08-09
US61/864,217 2013-08-09
US201361866416P 2013-08-15 2013-08-15
US61/866,416 2013-08-15
US201361869519P 2013-08-23 2013-08-23
US61/869,519 2013-08-23
US201361907525P 2013-11-22 2013-11-22
US61/907,525 2013-11-22
PCT/US2014/049848 WO2015021089A1 (en) 2013-08-09 2014-08-06 Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof

Publications (2)

Publication Number Publication Date
BR112016002738A2 true BR112016002738A2 (pt) 2017-12-05
BR112016002738B1 BR112016002738B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
UA116479C2 (uk) 2018-03-26
CN112898432A (zh) 2021-06-04
EP3030264B1 (en) 2019-01-09
KR20160042004A (ko) 2016-04-18
WO2015021089A1 (en) 2015-02-12
EA201690325A1 (ru) 2016-09-30
US10344092B2 (en) 2019-07-09
TW201536805A (zh) 2015-10-01
SG11201600855VA (en) 2016-03-30
CA2920021A1 (en) 2015-02-12
EA033658B1 (ru) 2019-11-13
DK3030264T3 (en) 2019-04-23
JP6395834B2 (ja) 2018-09-26
CN105611943A (zh) 2016-05-25
CL2016000293A1 (es) 2016-10-21
CN105611943B (zh) 2021-02-09
PT3030264T (pt) 2019-05-09
HUE043229T2 (hu) 2019-08-28
DOP2016000044A (es) 2016-04-15
IL244009A0 (en) 2016-04-21
EP3030264A4 (en) 2017-03-08
TN2016000042A1 (en) 2017-07-05
US20160194396A1 (en) 2016-07-07
PL3030264T3 (pl) 2019-08-30
AU2014306105B2 (en) 2019-05-23
AU2014306105A1 (en) 2016-02-18
PL3030264T4 (pl) 2019-10-31
EP3030264A1 (en) 2016-06-15
ES2720730T3 (es) 2019-07-24
GEP201706794B (en) 2017-12-11
KR102294018B1 (ko) 2021-08-27
JP2016527314A (ja) 2016-09-08
IL244009B (en) 2021-08-31
MX2016001741A (es) 2016-08-18
PH12016500242A1 (en) 2016-05-16
PE20160508A1 (es) 2016-05-21
CN112898432B (zh) 2023-08-29
CA2920021C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
PH12016500242A1 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
BR112016030447A2 (pt) diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
CO2019012998A2 (es) Proteínas de unión a antígenos trem2 y usos de estas
BR112019006781A2 (pt) receptores de antígeno quiméricos para o tratamento de câncer
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201591716A1 (ru) Антитела анти-il-33 и их применение
BR112015026823A2 (pt) Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada
BR112016016699A2 (pt) Anticorpos humanos para pd-1
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
BR112017002342A2 (pt) novos anticorpos e usos dos mesmos
BR112016003417A2 (pt) diacorpo otimizado por sequência capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, diacorpo biespecífico capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, composição farmacêutica, e uso da composição farmacêutica
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
BR112018075303A2 (pt) resumo método para tratar uma doença ou condição inflamatória, e método de redução ou inibição de uma resposta imune
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
BR112015018035A2 (pt) anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno
BR112016003030A2 (pt) anticorpos iib do receptor anti-fc-gama e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/08/2014, OBSERVADAS AS CONDICOES LEGAIS